Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, diazoxide choline controlled-release (DCCR), a tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into late-stage clinical development. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was founded in 1999 and is based in Redwood City, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SLNO
CUSIPN/A
Phone650-213-8444
Debt
Debt-to-Equity RatioN/A
Current Ratio8.14
Quick Ratio8.14
Price-To-Earnings
Trailing P/E Ratio-1.76
Forward P/E Ratio-1.74
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.45 million
Price / Sales35.14
Cash FlowN/A
Price / CashN/A
Book Value$1.38 per share
Price / Book1.72
Profitability
EPS (Most Recent Fiscal Year)($1.35)
Net Income$-15,660,000.00
Net MarginsN/A
Return on Equity-54.36%
Return on Assets-40.91%
Miscellaneous
Employees18
Outstanding Shares21,410,000
Market Cap$53.38 million
Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions
What is Soleno Therapeutics' stock symbol?
Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."
When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?
Soleno Therapeutics shares reverse split on the morning of Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.
How were Soleno Therapeutics' earnings last quarter?
Soleno Therapeutics Inc (NASDAQ:SLNO) issued its earnings results on Tuesday, August, 14th. The company reported ($0.36) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.12. View Soleno Therapeutics' Earnings History.
When is Soleno Therapeutics' next earnings date?
What price target have analysts set for SLNO?
3 equities research analysts have issued 12-month price objectives for Soleno Therapeutics' stock. Their predictions range from $4.00 to $14.00. On average, they anticipate Soleno Therapeutics' stock price to reach $7.3333 in the next year. This suggests a possible upside of 208.1% from the stock's current price. View Analyst Price Targets for Soleno Therapeutics.
What is the consensus analysts' recommendation for Soleno Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soleno Therapeutics.
Who are some of Soleno Therapeutics' key competitors?
Some companies that are related to Soleno Therapeutics include Helius Medical Technologies (HSDT), Fonar (FONR), Semler Scientific (SMLR), Second Sight Medical Products (EYES), Zynex Inc. common stock (ZYXI), IRIDEX (IRIX), BioSig Technologies (BSGM), Edap Tms (EDAP), Viveve Medical (VIVE), Stereotaxis (STXS), Digirad (DRAD), Dynatronics (DYNT), Aradigm (ARDM), Nexeon Medsystems (NXNN) and Nexeon Medsystems (NXNND).
Who are Soleno Therapeutics' key executives?
Soleno Therapeutics' management team includes the folowing people:
- Dr. Anish Bhatnagar, Pres, CEO & Director (Age 48)
- Mr. Anthony Wondka, Sr. VP of R&D (Age 56)
- Mr. David D. O'Toole, Consultant (Age 59)
- Mr. Jonathan R. Wolter, CFO & Principal Accounting Officer (Age 68)
- Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.
Has Soleno Therapeutics been receiving favorable news coverage?
News coverage about SLNO stock has trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Soleno Therapeutics earned a coverage optimism score of 0.23 on Accern's scale. They also assigned headlines about the company an impact score of 47.06 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Soleno Therapeutics.
Who are Soleno Therapeutics' major shareholders?
Soleno Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Vivo Capital LLC (22.05%), Trellus Management Company LLC (0.65%) and Dimensional Fund Advisors LP (0.22%). Company insiders that own Soleno Therapeutics stock include Edgar Engleman and Larry N Feinberg. View Institutional Ownership Trends for Soleno Therapeutics.
Which institutional investors are buying Soleno Therapeutics stock?
SLNO stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Trellus Management Company LLC and Dimensional Fund Advisors LP. Company insiders that have bought Soleno Therapeutics stock in the last two years include Edgar Engleman and Larry N Feinberg. View Insider Buying and Selling for Soleno Therapeutics.
How do I buy shares of Soleno Therapeutics?
Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Soleno Therapeutics' stock price today?
One share of SLNO stock can currently be purchased for approximately $2.38.
How big of a company is Soleno Therapeutics?
Soleno Therapeutics has a market capitalization of $53.38 million and generates $1.45 million in revenue each year. The company earns $-15,660,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. Soleno Therapeutics employs 18 workers across the globe.
How can I contact Soleno Therapeutics?
Soleno Therapeutics' mailing address is 1235 RADIO ROAD SUITE 110, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]
MarketBeat Community Rating for Soleno Therapeutics (NASDAQ SLNO)
MarketBeat's community ratings are surveys of what our community members think about Soleno Therapeutics and other stocks. Vote "Outperform" if you believe SLNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
